10601 results for 'EGF Receptor Inhibitors'

Cell Cycle · KinasesCyclins and Cyclin-Dependent Kinases: Regulation, Substrates and Mitotic ControlCDKs are inactive on their own. They require a cyclin partner, and because cyclin levels rise and fa

Interleukin signaling is involved in a number of biological processes, including cell growth and differentiation, inflammation and immunity. Interleukins are glycoproteins which act on hema

What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detect

The advent of immune checkpoint targeting marks a significant milestone in the oncological field, offering a beacon of hope for patients battling cancer. This innovative approach leverages the bod

Quick Facts About EldelumabWhat is Eldelumab?Eldelumab is a monoclonal antibody targeting TNFSF14 (LIGHT), a key regulator in immune system signaling, with potential applications in infl

What You Need to Know About ImalumabWhat is Imalumab?Imalumab is a monoclonal antibody targeting macrophage migration inhibitory factor (MIF), a key regulator of inflammation and immune

Imagine engineering a patient's own immune cells into precision-guided missiles against cancer—cells that can seek out and destroy tumors with remarkable specificity. This is the promise of CAR-T cell

Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst

Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther

Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat

Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What

Explore the complexities of Interleukin-10 (IL-10) signaling and regulation, a crucial aspect in immune response modulation and its dual roles in cancer development and therapy. Key Takeaways:

Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli

Low-dose IL-2 expands regulatory T cells. High-dose IL-2 expands the cells they exist to restrain. Same cytokine, same receptor family, opposite clinical intent — and the explanation is a receptor su

Quick Facts About IvuxolimabWhat is ivuxolimab?Ivuxolimab is a monoclonal antibody targeting CD47, a "don't eat me" signal that cancer cells exploit to evade immune destruction.How does

Chemokines are small signaling proteins that play a crucial role in the immune system by directing the movement of cells, orchestrating immune responses, and maintaining tissue homeostasis. The

An agonist antibody does not activate its receptor. It gets held still by something else, and the receptors underneath cluster because they are crowded. That sentence sounds like a technicality and i

COVID-19 Testing Results in 15 Minutes Accurate detection of IgM and IgG patient-generated antibodies with the rapid, point